Issues in reporting epidemiological studies: no data are given to support generalisation.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 544467)

Published in BMJ on January 15, 2005

Authors

David F Blackburn

Articles by these authors

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ (2007) 3.95

A pragmatic cluster randomized trial evaluating the impact of a community pharmacy intervention on statin adherence: rationale and design of the Community Pharmacy Assisting in Total Cardiovascular Health (CPATCH) study. Trials (2010) 1.42

Changes in adherence to evidence-based medications in the first year after initial hospitalization for heart failure: observational cohort study from 1994 to 2003. Circ Cardiovasc Qual Outcomes (2009) 0.98

Retrospective observational assessment of statin adherence among subjects patronizing different types of community pharmacies in Canada. J Manag Care Pharm (2009) 0.98

Risk of heart failure in patients with recent-onset type 2 diabetes: population-based cohort study. J Card Fail (2008) 0.92

The Collaborative Cardiovascular Risk Reduction in Primary Care (CCARP) study. Pharmacotherapy (2010) 0.84

Collaborative Cardiovascular Risk Reduction in Primary Care II (CCARP II): Implementation of a systematic case-finding process for patients with uncontrolled risk factors. Can Pharm J (Ott) (2013) 0.77

Pharmacist intervention in cardiac rehabilitation: a randomized controlled trial. J Cardiopulm Rehabil Prev (2012) 0.76

Multiple-domain Versus Single-domain Measurements of Socioeconomic Status (SES) for Predicting Nonadherence to Statin Medications: An Observational Population-based Cohort Study. Med Care (2016) 0.76

Evaluation of a refill synchronization program in two community pharmacies. J Am Pharm Assoc (2003) (2016) 0.75

Do prior authorization policies discourage first-line antipsychotic use in patients newly discharged from a hospitalization for schizophrenia in Saskatchewan? J Popul Ther Clin Pharmacol (2014) 0.75

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension due to primary aldosteronism: a case for exclusion. Ann Pharmacother (2006) 0.75